Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Inclusion Criteria:

• Participants must have advanced, unresectable, and/or metastatic solid tumormalignancy that is histologically or cytologically confirmed.

• Patients must have received at least 2 lines of therapy in the advanced/metastaticsetting (if 2 lines exist) and have no other possible therapies or refuse therapiesthat have shown clinical benefit for their condition.

• ECOG performance status <1

• Ability to understand and the willingness to sign a written informed consentdocument.

• Patients must have measurable disease

• Ability to swallow oral medications

Exclusion Criteria:

• Participants who have had chemotherapy or radiotherapy within 3 weeks

• Participants may not be receiving any other investigational agents.

• Active hepatitis B or hepatitis C infection.

• Active or untreated gastric or duodenal ulcer

• Symptomatic bowel obstruction within 3 months prior to screening visit.

• Symptomatic ascites in the last 4 weeks

Other protocol defined inclusion/exclusion criteria may apply.